VJHemOnc is committed to improving our service to you

EHA 2019 | Glasdegib therapy for MDS and AML

VJHemOnc is committed to improving our service to you

David Sallman

David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the use of glasdegib therapy for relapsed/refractory myelodysplastic syndromes and oligoblastic acute myeloid leukemia at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter